This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genor Biopharma Holdings Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Feng Guo

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.4yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	2.3yrs
Yönetim Kurulu ortalama görev süresi	1.1yrs

Son yönetim güncellemeleri

Recent updates

CEO

Feng Guo (52 yo)

2.4yrs

Görev süresi

Dr. Feng Guo Ph D., serves as Chairman of the Board for Genor BioPharma Co., Ltd. since November 2021.He serves as Chairman at Genor Biopharma Holdings Limited since November 02, 2021. Dr. Guo has been th...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Feng Guo	CEO & Chairman	2.4yrs	Veri yok	0.29% HK$ 3.6m
Qibin Liang	Chief Technology Officer	1.7yrs	Veri yok	Veri yok
Shuhua Han	Chief Scientist	1.7yrs	Veri yok	Veri yok
Xiaojing Zhu	Vice President of Human Resources	no data	Veri yok	Veri yok
Tong Li	Chief Medical Officer	2.1yrs	Veri yok	Veri yok
Cheery Chen	Chief Regulatory Officer	1.7yrs	Veri yok	Veri yok
Tak Wai Ip	Company Secretary	less than a year	Veri yok	Veri yok
Huiyang Cheng	Vice President of Global Strategy	2.8yrs	Veri yok	Veri yok
Jun Lin	Vice President of Quality Analysis	2.7yrs	Veri yok	Veri yok
Yao Chen	Vice President of Regulatory Affairs	3.2yrs	Veri yok	Veri yok
Qingtang Duan	General Manager of Yuxi Genor	3.1yrs	Veri yok	Veri yok
Chengyi Weng	Vice President of Finance	no data	Veri yok	Veri yok

2.3yrs

Ortalama Görev Süresi

48yo

Ortalama Yaş

Deneyimli Yönetim: 6998 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Feng Guo	CEO & Chairman	2.4yrs	Veri yok	0.29% HK$ 3.6m
David J. Kerr	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Leonard B. Saltz	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Alex A. Adjei	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
Wen Chen	Independent Non-Executive Director	2.3yrs	Veri yok	Veri yok
Yu Chen	Non-Executive Director	3.8yrs	Veri yok	Veri yok
Edwin Fung	Independent Non-Executive Director	2.3yrs	Veri yok	Veri yok
Honghao Zhou	Independent Non-Executive Director	2yrs	Veri yok	Veri yok
Dong Lyu	Non Executive Director	less than a year	Veri yok	Veri yok
Zhijian Chen	Chairman of Scientific Advisory Board	1.3yrs	Veri yok	Veri yok
Yangxin Fu	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok
John F. Seymour	Member of Scientific Advisory Board	less than a year	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6998 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

This company listing is no longer active

Genor Biopharma Holdings Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Recent updates

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

CEO

Görev süresi

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş